ArticleThe New England journal of medicine2023
Multiple Cerebral Hemorrhages in a Patient Receiving Lecanemab and Treated with t-PA for Stroke.
Open access · bronzeAbstract readLetterComment
In one paragraph
Article in The New England journal of medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 130 papers, 4 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
130citing papers in PubMed, 4 pooled it
40.9field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
130 citing papers in PubMed, 4 syntheses or guidelines pooled it, 200 citations in OpenAlex.
- Real-world safety and efficacy of lecanemab in the treatment of Alzheimer's disease: a systematic review and meta-analysis.Journal of neurology · 2026Pooled it
- Regulatory, clinical, and post-marketing challenges of lecanemab for Alzheimer's disease: insights from real-world data.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2026Pooled it
- Safety profiles of lecanemab: A systematic review and meta-analysis of randomized controlled trials and real-world evidence.The journal of prevention of Alzheimer's disease · 2026Pooled it
- The efficacy and safety of lecanemab 10 mg/kg biweekly compared to a placebo in patients with Alzheimer's disease: a systematic review and meta-analysis of randomized controlled trials.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2024Pooled it
- Phase 2A Proof-of-Concept Double-Blind, Randomized, Placebo-Controlled Trial of Nicotinamide in Early Alzheimer Disease.Neurology · 2025Trial
- Implications of the Approval of Lecanemab for Alzheimer Disease Patient Care: Incremental Step or Paradigm Shift?Neurology · 2023Trial
- Article
- Unconventional animal models of Alzheimer's disease and aging: key insights from the UAMAA 2026 conference.Lab animal · 2026Article
- [Antibody therapy in Alzheimer's disease].Zeitschrift fur Gerontologie und Geriatrie · 2026Review
- Exploring the Neuroprotective Effects of Walnut (International journal of molecular sciences · 2026Article
- Clinical Practice Outcomes With Lecanemab for Alzheimer Disease.Neurology open access · 2026Article
- Anti-Amyloid Antibodies in the Treatment of Alzheimer's Disease: An Umbrella Review.Journal of clinical medicine · 2026Review
- A Niacin-α-Lipoic Acid Hybrid Ameliorates Alzheimer's Disease Pathology in Mouse Models.ACS pharmacology & translational science · 2026Article
- Factors associated with intracerebral hemorrhage in confirmed cerebral amyloid angiopathy.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026Article
- Ultrasound-Mediated Thrombolysis: From Mechanistic Insights to Advanced Nanoplatforms and Clinical Translation.Advanced healthcare materials · 2026Review
- [Progress and controversies surrounding disease-modifying treatments for Alzheimer's disease].Atencion primaria · 2026Article
- Anti-amyloid immunotherapy drives APOE4 specific increases in glial reactivity, perivascular immune activation, and ARIA-like events.bioRxiv : the preprint server for biology · 2026Article
- Early binding of anti-amyloid antibodies to CAA drives complement activation, inflammation and ARIA in mice.Molecular neurodegeneration · 2026Article
- Ex vivo comparison of ACU193 and lecanemab reveals binding differences in mouse brain.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026Article
- Are we ready for amyloid-related imaging abnormalities (ARIA) monitoring? A European survey among neuroradiologists and neurologists by the ESNR/EAN Working Group.European radiology · 2026Article
70 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
- Comment on
Authors and funding
12 authors at 1 institution in 1 country.
Nicholas J ReishNorthwestern University Feinberg School of Medicine, Chicago, IL sherry.chou@nm.org.
Pouya JamshidiNorthwestern University Feinberg School of Medicine, Chicago, IL sherry.chou@nm.org.
Brian StammNorthwestern University Feinberg School of Medicine, Chicago, IL sherry.chou@nm.org.
Margaret E FlanaganNorthwestern University Feinberg School of Medicine, Chicago, IL sherry.chou@nm.org.
Elizabeth SuggNorthwestern University Feinberg School of Medicine, Chicago, IL sherry.chou@nm.org.
Mengxuan TangNorthwestern University Feinberg School of Medicine, Chicago, IL sherry.chou@nm.org.
Kelly L DonohueNorthwestern University Feinberg School of Medicine, Chicago, IL sherry.chou@nm.org.
Matthew McCordNorthwestern University Feinberg School of Medicine, Chicago, IL sherry.chou@nm.org.
Chase KrumpelmanNorthwestern University Feinberg School of Medicine, Chicago, IL sherry.chou@nm.org.
Marek-Marsel MesulamNorthwestern University Feinberg School of Medicine, Chicago, IL sherry.chou@nm.org.
Rudolph CastellaniNorthwestern University Feinberg School of Medicine, Chicago, IL sherry.chou@nm.org.ORCID 0000-0002-5414-3184
Sherry H-Y ChouNorthwestern University Feinberg School of Medicine, Chicago, IL sherry.chou@nm.org.ORCID 0000-0002-5483-2908
Northwestern University · US
Funding
Research Education Core FP30AG072977 · NIA · NORTHWESTERN UNIVERSITY AT CHICAGO · PI Hui Zhang · 2021 to 2026
$26.3MCharacterize neuronal and glial cell-specific vulnerability to proteinopathies in Alzheimer's disease using multimodal single-nuclei genomic and epigenomic approachesR01AG082118 · NIA · CLEVELAND CLINIC LERNER COM-CWRU · PI BONAKDARPOUR, BORNA, CHENG, FEIXIONG · 2023 to 2025
$2.4MExploring the origins of myelin abnormalities in normal ageing and in vascular dementiaRF1AG072080 · NIA · NORTHWESTERN UNIVERSITY AT CHICAGO · PI FLANAGAN, MARGARET E, POPKO, BRIAN J · 2021 to 2021
$2.2MExploring the origins of myelin abnormalities in normal ageing and in vascular dementiaR01AG072080 · NIA · NORTHWESTERN UNIVERSITY AT CHICAGO · PI FLANAGAN, MARGARET E, POPKO, BRIAN J · 2024 to 2025
$1.4Mnvestigating the role of neuroinflammation in Limbic-predominant age related TDP43 encephalopathyK08AG065463 · NIA · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI FLANAGAN, MARGARET E · 2020 to 2024
$816kMicroRNA Endotypes of Systemic Inflammation in Sub-Arachnoid hemorrhaGE (MESSAGE)R21NS113037 · NINDS · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI CHOU, SHERRY HSIANG-YI · 2019 to 2019
$390kNIA NIH HHS K08 AG065463NIA NIH HHS P30 AG072977NIA NIH HHS R01 AG072080NIA NIH HHS R01 AG082118NIA NIH HHS RF1 AG072080NINDS NIH HHS R21 NS113037
Abstract
PubMed holds no abstract for this paper.
Indexed as
Antibodies, Monoclonal, HumanizedCerebral HemorrhageFibrinolytic AgentsStrokeTissue Plasminogen ActivatorBrain IschemiaHumansIntracranial HemorrhagesTreatment OutcomeAntibodies, Monoclonal, HumanizedFibrinolytic AgentslecanemabTissue Plasminogen Activator
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.